Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuated-dose rituximab with chemotherapy in chronic lymphocytic leukaemia
ISRCTN16544962Phase 2Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of rituximab, fludarabine, cyclophosphamide and mitoxantrone in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Complete response rate. Started Jan 2009; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamidemitoxantrone
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN16544962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16544962.